Our study retrospectively highlighted the feasibility and safety of the combined administration of apatinib combined with PD-1 inhibitors for patients with previously treated advanced GC in the real world, which indicated that apatinib plus PD-1 inhibitor therapy exhibited promising effectiveness acceptable tolerance for patients with previously treated advanced GC preliminarily. This evidence concerns the gene PDCD1 and gastric cancer.